{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T23:56:57Z","timestamp":1768003017682,"version":"3.49.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008130","name":"Pusan National University Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012403","name":"Texas Biomedical Research Institute","doi-asserted-by":"publisher","award":["20200016"],"award-info":[{"award-number":["20200016"]}],"id":[{"id":"10.13039\/100012403","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ejso.2022.10.020","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T21:41:35Z","timestamp":1667338895000},"page":"392-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["HER2 status based on breast cancer guidelines as a useful prognostic marker of T2 gallbladder cancer"],"prefix":"10.1016","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2277-1570","authenticated-orcid":false,"given":"Chae Hwa","family":"Kwon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4132-7662","authenticated-orcid":false,"given":"Hyung Il","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7208-7753","authenticated-orcid":false,"given":"Dong Uk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0256-9781","authenticated-orcid":false,"given":"Sung Yong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3268-1763","authenticated-orcid":false,"given":"Suk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6465-9811","authenticated-orcid":false,"given":"So Jeong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8893-2704","authenticated-orcid":false,"given":"Da Ye","family":"Jeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2022.10.020_bib1","author":"World cancer research fund international"},{"key":"10.1016\/j.ejso.2022.10.020_bib2","doi-asserted-by":"crossref","first-page":"220","DOI":"10.14701\/ahbps.22-041","article-title":"Incidence, mortality and survival of gallbladder, extrahepatic bile duct, and pancreatic cancer using Korea central cancer registry database: 1999-2019","volume":"26","author":"Kang","year":"2022","journal-title":"Ann Hepatobiliary Pancreat Surg"},{"key":"10.1016\/j.ejso.2022.10.020_bib3","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s11605-007-0109-z","article-title":"Actual recurrence patterns and risk factors influencing recurrence after curative resection with stage II gallbladder carcinoma","volume":"11","author":"Park","year":"2007","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.ejso.2022.10.020_bib4","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11605-009-1140-z","article-title":"Risk factors influencing recurrence, patterns of recurrence, and the efficacy of adjuvant therapy after radical resection for gallbladder carcinoma","volume":"14","author":"Kim","year":"2010","journal-title":"J\u00a0Gastrointest Surg"},{"key":"10.1016\/j.ejso.2022.10.020_bib5","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3857\/roj.2017.00388","article-title":"Patterns of initial failure after resection for gallbladder cancer: implications for adjuvant radiotherapy","volume":"35","author":"Kim","year":"2017","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.ejso.2022.10.020_bib6","article-title":"Benefit of adjuvant chemoradiotherapy in resected gallbladder carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejso.2022.10.020_bib7","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1200\/JCO.2014.59.7591","article-title":"Biliary tract cancers: understudied and poorly understood","volume":"33","author":"Chan","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2022.10.020_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/CCO.0b013e3283620fd8","article-title":"State-of \u2013the art in the management of locally advanced and metastatic gallbladder cancer","volume":"25","author":"McNamara","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ejso.2022.10.020_bib9","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1126\/science.3012781","article-title":"The production of human c-erbB- gene: a 185-kilodalton glycoprotein with tyrosine kinase activity","volume":"232","author":"Akiyama","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.ejso.2022.10.020_bib10","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ejso.2022.10.020_bib11","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","article-title":"Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial","volume":"376","author":"Bang","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2022.10.020_bib12","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1080\/15384047.2015.1113356","article-title":"Molecular profiling of 6,892 colorectal cancer samples suggests different possible treatment options specific to metastatic sites","volume":"16","author":"El-Deiry","year":"2015","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ejso.2022.10.020_bib13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s00428-015-1898-1","article-title":"A\u00a0significant subgroup of resectable bladder cancer patients has an HER2 positive status","volume":"468","author":"Yochida","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1016\/j.ejso.2022.10.020_bib14","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1038\/s41598-020-58777-y","article-title":"Expression of female sex hormone receptors, connective tissue growth factors and HER 2 in gallbladder cancer","volume":"10","author":"Hryciuk","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ejso.2022.10.020_bib15","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1002\/path.1779","article-title":"Amplification and overexpression of c-erbB-2, epithermal growth factor receptor, and c-met in biliary tract cancer","volume":"206","author":"Nakazawa","year":"2005","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.ejso.2022.10.020_bib16","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.3748\/wjg.15.4511","article-title":"EGFR and HER2 expression in advanced biliary tract cancer","volume":"15","author":"Harder","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ejso.2022.10.020_bib17","first-page":"42","article-title":"Overexpresion of HER2\/neu Gene: a new therapeutic possibility for patients with advanced gallbladder cancer","volume":"7","author":"Roa","year":"2014","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.ejso.2022.10.020_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.4103\/0377-4929.94862","article-title":"Role of C-erbB2 expression in gallbladder cancer","volume":"55","author":"Kumari","year":"2012","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.ejso.2022.10.020_bib19","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000450999","article-title":"Prognostic significance of HER-2 and p53 expression in gallbladder carcinoma in North Indian patients","volume":"91","author":"Singh","year":"2016","journal-title":"Oncology"},{"key":"10.1016\/j.ejso.2022.10.020_bib20","first-page":"3903","article-title":"Expression of human epidermal growth factor receptor (Her 2\/neu) and proliferative marker Ki-67: association with clinicopathological parameters in gallbladder carcinoma","volume":"17","author":"Pujani","year":"2016","journal-title":"Asian Pac J Cancer Prev APJCP"},{"key":"10.1016\/j.ejso.2022.10.020_bib21","article-title":"Her2 positivity is affected by the papillary structure and has a bidirectional prognostic value for gallbladder carcinoma","volume":"13","author":"Chen","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.ejso.2022.10.020_bib22","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.5858\/arpa.2016-0331-CP","article-title":"HER2 testing and clinical decision making in gastroesophageal adenocarcinoma: guideline from the college of American pathologists, American society for clinical pathology, and American society of clinical Oncology","volume":"140","author":"Bartley","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.ejso.2022.10.020_bib23","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update","volume":"36","author":"Wolff","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2022.10.020_bib24","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1440-1746.2011.07048.x","article-title":"Gallbladder cancer: can newer insights improve the outcome?","volume":"27","author":"Dutta","year":"2012","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.ejso.2022.10.020_bib25","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1093\/annonc\/mdt540","article-title":"Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials","volume":"25","author":"Valle","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2022.10.020_bib26","article-title":"First-line chemotherapy in advanced biliary tract cancer ten years after the ABC-02 trial: \"and yet it moves","volume":"27","author":"Rizzo","year":"2021","journal-title":"Cancer Treat Res Commun"},{"key":"10.1016\/j.ejso.2022.10.020_bib27","first-page":"3317","article-title":"Prognostic significance of tumor location in T2 Gablladder cancer: a systematic review and meta-analysis","volume":"10","author":"Kang","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.ejso.2022.10.020_bib28","first-page":"129","article-title":"Surgical outcome and prognostic factors in patients with gallbladder carcinoma","volume":"18","author":"Hong","year":"2014","journal-title":"KJHBPS"},{"key":"10.1016\/j.ejso.2022.10.020_bib29","doi-asserted-by":"crossref","first-page":"140","DOI":"10.5009\/gnl15080","article-title":"Effect of surgical methods and tumor location on survival and recurrence patterns after curative resection in patients with T2 gallbladder cancer","volume":"10","author":"Jung","year":"2016","journal-title":"Gut Liver"},{"key":"10.1016\/j.ejso.2022.10.020_bib30","doi-asserted-by":"crossref","first-page":"2635","DOI":"10.1007\/s00268-013-2187-2","article-title":"Role of cholecystectomy and lymph node dissection in patients with T2 gallbladder cancer","volume":"37","author":"Kim","year":"2013","journal-title":"World J Surg"},{"key":"10.1016\/j.ejso.2022.10.020_bib31","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/S1072-7515(01)00814-6","article-title":"Surgical treatment of patients with T2 gallbladder carcinoma invading the subserosal layer","volume":"192","author":"chijiiwa","year":"2001","journal-title":"J\u00a0Am Coll Surg"},{"key":"10.1016\/j.ejso.2022.10.020_bib32","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/his.12357","article-title":"The updated ASCO\/CAP guideline recommendations for HER2 testing in the management of invasive breast cancer: a critical review of their implications for routine practice","volume":"64","author":"Rakha","year":"2014","journal-title":"Histopathology"},{"key":"10.1016\/j.ejso.2022.10.020_bib33","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1111\/j.1365-2559.2008.03028.x","article-title":"Assessment of a HER2 scoring system for gastric cancer: results from a validation study","volume":"52","author":"Hofmann","year":"2008","journal-title":"Histopathology"},{"key":"10.1016\/j.ejso.2022.10.020_bib34","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/modpathol.2011.198","article-title":"HER2 testing in gastric cancer: a practical approach","volume":"25","author":"R\u00fcschoff","year":"2012","journal-title":"Mod Pathol"},{"key":"10.1016\/j.ejso.2022.10.020_bib35","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jmoldx.2012.01.012","article-title":"Quantitative analysis of diagnostic guidelines for HER2 status assessment","volume":"14","author":"Stenzinger","year":"2012","journal-title":"J\u00a0Mol Diagn"},{"key":"10.1016\/j.ejso.2022.10.020_bib36","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: results from MyPathway, an open- label, phase IIa multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2022.10.020_bib37","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ejso.2022.10.020_bib38","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.3390\/cancers12082308","article-title":"Evolution of the experimental models of cholangiocarcinoma","volume":"12","author":"Massa","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejso.2022.10.020_bib39","first-page":"1476","article-title":"EGFR target therapy combined with Gemox for advanced biliary tract cancers: a meta-analysis based on RCTs","volume":"9","author":"Cai","year":"2018","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.ejso.2022.10.020_bib40","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1158\/2159-8290.CD-15-1442","article-title":"Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma","volume":"6","author":"Saha","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejso.2022.10.020_bib41","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II Study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2022.10.020_bib42","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1080\/13543784.2021.1897102","article-title":"Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer","volume":"30","author":"Rizzo","year":"2021","journal-title":"Expet Opin Invest Drugs"},{"key":"10.1016\/j.ejso.2022.10.020_bib43","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1158\/2159-8290.CD-17-0245","article-title":"New horizon for precision medicine in biliary tract cancers","volume":"7","author":"Valle","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ejso.2022.10.020_bib44","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s10555-016-9645-x","article-title":"HER2\/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","volume":"36","author":"Galdy","year":"2016","journal-title":"Cancer Metastasis Rev"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798322007120?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798322007120?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:46:41Z","timestamp":1760060801000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798322007120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0748798322007120"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2022.10.020","relation":{},"ISSN":["0748-7983"],"issn-type":[{"value":"0748-7983","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HER2 status based on breast cancer guidelines as a useful prognostic marker of T2 gallbladder cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2022.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}